Open AccessClinical cure and liver fibrosis reversal after postoperative antiviral combination therapy in hepatitis B-associated non-cirrhotic hepatocellular carcinoma: A case report
Author(s) -
Xueping Yu,
Qin Lin,
Zhi-peng Huang,
Weishan Chen,
Minghui Zheng,
Yijuan Zheng,
Julan Li,
Zhijun Su
Publication year - 2021
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v9.i3.714
Subject(s) - medicine , hepatocellular carcinoma , antiviral therapy , gastroenterology , cirrhosis , liver fibrosis , fibrosis , combination therapy , carcinoma , hepatitis b , chronic hepatitis , virology , virus
The incidence of hepatocellular carcinoma (HCC) is high in China, and approximately 15%-20% of HCC cases occur in the absence of cirrhosis. Compared with patients with cirrhotic HCC, those with non-cirrhotic HCC have longer postoperative tumor-free survival. However, the overall survival time is not significantly increased, and the risk of postoperative recurrence remains. Strategies to improve the postoperative survival rate in these patients are currently required.